Tvardi Therapeutics, Inc. (TVRD) Live Share Price, Invest From India

Tvardi Therapeutics, Inc. Stock Performance

as on May 7, 2026 at 6:59 am IST

Day's Low
Day's High
$3.47
Day's Price Range
$3.79
$3.67
5.45%
Downside
3.27%
Upside
52 Week's Low
52 Week's High
$2.75
52-Week Price Range
$43.65
$3.67
25.07%
Downside
1089.37%
Upside

Tvardi Therapeutics, Inc. share price movements today

Previous Close: $3.69
Open: $3.68
Volume: 116.6K
Day's Low - High: $3.47 - $3.79
52 Week Low - High: $2.75 - $43.65

Tvardi Therapeutics, Inc. Historical Returns

1 Month Return: + 23.83 %
3 Month Return: -0.81 %
1 Year Return: -85.94 %
3 Year Return: 0 %
5 Year Return: 0 %

Tvardi Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Tvardi Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$33.2M

EPS (TTM)

-2.035

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-237.81%

Tvardi Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Tvardi Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Tvardi Therapeutics, Inc.	NA	$33.2M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$40.2B	127.94%	75.85	12.55%
Vertex Pharmaceuticals Inc	BUY	$107.9B	99.08%	25.18	32.94%
BeiGene, Ltd.	NA	$33.1B	NA	120.44	5.37%
Regeneron Pharmaceuticals Inc	BUY	$73.6B	40.83%	17.13	29.65%

Stock Returns calculator for Tvardi Therapeutics, Inc. Stock including INR - Dollar returns

The Tvardi Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Tvardi Therapeutics, Inc. investment value today

Current value as on today

₹15,690

Returns

-₹84,310

(-84.31%)

Returns from Tvardi Therapeutics, Inc. Stock

-₹86,019 (-86.02%)

Dollar Impact

₹1,709 (+1.71%)

Indian Investors' Interest in Tvardi Therapeutics, Inc. Stock

Search interest for Tvardi Therapeutics, Inc. Stock has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.

Time period: April 7, 2026 to May 7, 2026

Change:-48% versus previous 30 day period

Tvardi Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	4	3	2	0	2	1	2	-	-	-
Gross Profit	3	2	1	0	2	1	2	0	-	-
Operating Income	-28	-32	-29	-7	-5	-10	-2	-8	-5	-7
EBITDA	-27	-31	-28	-6	-5	-10	-2	-8	-5	-7
Interest Expense	-	-	1	1	1	2	2	-	-	-
Depreciation	-	0	0	0	0	0	-	0	0	0
Income Before Tax	-28	-32	-30	-6	-5	-12	-4	4	-5	-7
Income Tax Expense	-	-	-	-	-	0	-	-	-	-
Net Income	-28	-32	-30	-6	-5	-12	-4	4	-5	-7
Net Profit Margin	-576.08%	-1076.46%	-1437.75%	-703.83%	-215.69%	-873.33%	-190.97%	0.00%	0.00%	0.00%

Tvardi Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	135	23	41	20	7	-
Gross Profit	-	21	34	14	6	0
Operating Income	5	-89	-87	-121	-55	-26
EBITDA	8	-86	-83	-117	-62	-26
Interest Expense	-	-	0	-	8	-
Depreciation	-	-	0	0	0	0
Income Before Tax	7	-88	-85	-118	-71	-18
Income Tax Expense	0	-	-	-	0	-
Net Income	8	-88	-85	-118	-70	-18
Net Profit Margin	6.23%	-384.06%	-204.16%	-565.21%	-992.95%	0.00%

Tvardi Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-4	-30	-20	-12	-7	-4	0	-5	-7
Operating Cash Flow	-5	-30	-12	-13	-4	-4	-8	-4	-5
Investing Cash Flow	-30	25	15	2	5	-	-20	5	5
Financing Cash Flow	36	0	0	0	-1	1	22	0	0
Change in Cash	-5	-5	2	-10	0	-3	-13	0	0

Tvardi Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-88	-20	-17	-70	-18
Operating Cash Flow	-60	-17	-21	-60	-23
Investing Cash Flow	-4	-22	22	48	-10
Financing Cash Flow	46	0	0	-3	22
Change in Cash	-18	-39	1	-14	-10

Insights on Tvardi Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, TVRD stock has moved up by 17.1%
NO EFFECT
Against Peers
In the last 1 year, BeOne Medicines Ltd has given 28.1% return, outperforming this stock by 113.9%

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Organisation	Tvardi Therapeutics, Inc.
Headquarters	3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478
Industry	Biotechnology
CEO	Dr. Imran Alibhai Ph.D.
E-voting on shares	Click here to vote

Key Management of Tvardi Therapeutics, Inc.

Name	Title
Mr. Dan Conn J.D., M.B.A.	CFO & Corporate Secretary
Dr. Jeffrey Larson DABT, Ph.D.	Senior Vice President of R&D
Mr. Stephen O'Brien CPA	VP of Finance & Corporate Controller
Dr. Yixin Chen Ph.D.	Vice President of CMC
Dr. Michael T. Lewis Ph.D.	Co-Founder & Scientific Advisory Board Member
Dr. Imran Alibhai Ph.D.	CEO & Director
Dr. John Kauh M.D.	Chief Medical Officer
Mr. David J. Tweardy M.D.	Co-Founder & Scientific Advisory Board Member
Dr. Ronald A. DePinho M.D.	Co-Founder & Chairman of Scientific Advisory Board

FAQs

What is Tvardi Therapeutics, Inc. share price today?

Tvardi Therapeutics, Inc. share price today is $3.67 as on May 7, 2026 at 1:29 am IST at the close of the market. Tvardi Therapeutics, Inc. share today touched a day high of $3.79 and a low of $3.47.

What is the 52 week high and 52 week low for Tvardi Therapeutics, Inc. share?

Tvardi Therapeutics, Inc. share touched a 52 week high of $43.65 on October 10, 2025 and a 52 week low of $2.75 on April 7, 2026. Tvardi Therapeutics, Inc. stock price today i.e. May 7, 2026 at 1:29 am IST is closed at $3.67,which is 91.59% down from its 52 week high and 33.45% up from its 52 week low.

What is Tvardi Therapeutics, Inc.'s market capitalisation today?

Tvardi Therapeutics, Inc. market capitalisation is $0.00T as on May 7, 2026 at 1:29 am IST.

How to invest in Tvardi Therapeutics, Inc. Stock (TVRD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Tvardi Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tvardi Therapeutics, Inc. Shares that will get you 0.4087 shares as per Tvardi Therapeutics, Inc. share price of $3.67 per share as on May 7, 2026 at 1:29 am IST.

What is the minimum amount required to buy Tvardi Therapeutics, Inc. Stock (TVRD) from India?

Indian investors can start investing in Tvardi Therapeutics, Inc. (TVRD) shares with as little as ₹94.61 or $1 (as of May 7, 2026 at 10:56 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹946.10 in Tvardi Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on May 7, 2026 at 10:56 am IST). Based on Tvardi Therapeutics, Inc. share’s latest price of $3.67 as on May 7, 2026 at 1:29 am IST, you will get 2.7248 shares of Tvardi Therapeutics, Inc.. Learn more about fractional shares .